Deletion of the Prostaglandin E2EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease
Open Access
- 2 November 2005
- journal article
- research article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 25 (44), 10180-10187
- https://doi.org/10.1523/jneurosci.3591-05.2005
Abstract
Epidemiological studies demonstrate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) in normal aging populations reduces the risk of developing Alzheimer's disease (AD). NSAIDs inhibit the enzymatic activity of cyclooxygenase-1 (COX-1) and inducible COX-2, which catalyze the first committed step in the synthesis of prostaglandins. These studies implicate COX-mediated inflammation as an early and potentially reversible preclinical event; however, the mechanism by which COX activity promotes development of AD has not been determined. Recent studies implicate the prostaglandin E2(PGE2) E prostanoid subtype 2 (EP2) receptor in the development of the innate immune response in brain. Here, we report that deletion of the PGE2EP2 receptor in the APPSwe-PS1ΔE9 model of familial AD results in marked reductions in lipid peroxidation in aging mice. This reduction in oxidative stress is associated with significant decreases in levels of amyloid-β (Aβ) 40 and 42 peptides and amyloid deposition. Aged APPSwe-PS1ΔE9 mice lacking the EP2 receptor harbor lower levels of β C-terminal fragments, the product of β-site APP cleaving enzyme (BACE1) processing of amyloid precursor protein. Increases in BACE1 processing have been demonstrated in models of aging and AD and after oxidative stress. Our results indicate that PGE2signaling via the EP2 receptor promotes age-dependent oxidative damage and increased Aβ peptide burden in this model of AD, possibly via effects on BACE1 activity. Our findings identify EP2 receptor signaling as a novel proinflammatory and proamyloidogenic pathway in this model of AD, and suggest a rationale for development of therapeutics targeting the EP2 receptor in neuroinflammatory diseases such as AD.Keywords
This publication has 52 references indexed in Scilit:
- Post-translational processing of beta-secretase in Alzheimer's diseaseProteomics, 2005
- Demonstration of BACE (β-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopyJournal of Cell Science, 2004
- Increased β‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjectsAnnals of Neurology, 2004
- The LPS receptor (CD14) links innate immunity with Alzheimer's diseaseThe FASEB Journal, 2003
- Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependentJournal of Neurochemistry, 2002
- Increased expression of the amyloid precursor β‐secretase in Alzheimer's diseaseAnnals of Neurology, 2002
- Cyclooxygenase‐independent actions of cyclooxygenase inhibitorsThe FASEB Journal, 2001
- Factors that Influence the Suppression of Pulmonary Antibacterial Defenses in Mice Exposed to OzoneExperimental Lung Research, 1993
- Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionatorThe Anatomical Record, 1991
- Prostaglandin-mediated suppression of macrophage phagocytosis of Listeria monocytogenesCellular Immunology, 1987